Founded in 2022, Hummsa Biotech operates in Health Tech offering a pipeline of oral, small-molecule therapies aimed at reshaping the management of metabolic and age-related diseases. The company focus...
Funding stage:
Pre-Seed
Last funding:
31/05/2024
Total funding:
$314.77K+
Revenue:
Investors
Employee count:
2
Last 90d
2
Last 90d
Hummsa Biotech: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders14
Latest Filing Date29 Sept 2024- Funding Events9
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Hummsa Biotech
As of 30 September 2024, Hummsa Biotech's equity is held by 14 shareholders, with the top three being Harshad Lalwani, Sanjana Malhotra, and First Founder Investment Trust.
Harshad Lalwani holds the largest stake in Hummsa Biotech at 42.5% as of 30 September 2024.
As of 30 September 2024, founders collectively hold 50.4% equity in Hummsa Biotech.
As of 30 September 2024, investors collectively hold 21.1% equity in Hummsa Biotech.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links